MedicarePartD.guide

A non-government resource built from CMS public data

Rinvoq on SilverScript Choice (S5601-028)

upadacitinib

Covered, with prior authorization required.

Tier 5 (specialty tier). Quantity limit of 168 per 365 days.

$1,627.94
Patient pays / month, after deductible
$2,089.19
Patient pays / month, before the $615.00 deductible
Not offered
Patient pays / 90 days by mail
$0
After the yearly $2,100.00 out-of-pocket cap

RINVOQ 45 mg Tablet, Extended Release at a preferred retail pharmacy, from the plan's negotiated price of $6,511.76 for a month. Other covered strengths are listed below.

Prior authRequired on all 4 covered forms· The plan decides within 72 hours, or 24 if expedited· If denied, the prescriber can ask the plan to reconsider (an appeal)
All 4 covered strengths and forms
FormTierPatient pays / monthLimits
RINVOQ 45 mg Tablet, Extended Release5$1,627.94PA · 168 per 365 days
RINVOQ 15 mg Tablet, Extended Release5$1,744.24PA · 30 per 30 days
RINVOQ 30 mg Tablet, Extended Release5$1,744.24PA · 30 per 30 days
RINVOQ 1 mg/mL Solution5$1,674.49PA · 360 per 30 days

Other JAK inhibitors on this plan

Verify with the plan before prescribing or filling. Member services: (866)235-5660. Data from the CMS 2026 Part D formulary and pricing files. Full plan details

Plan ID s5601-028